Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2006-06-06
2006-06-06
Chernyshev, Olga N. (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S007100, C436S500000, C424S602000, C424S682000, C514S001000, C514S167000, C530S350000
Reexamination Certificate
active
07056655
ABSTRACT:
The present invention relates to novel methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism. One determines and monitors the level of parathyroid hormone agonist and parathyroid hormone antagonist in the renal patient. The parathyroid hormone suppressing therapeutic is administered to the patient so as to minimize the level of parathyroid hormone antagonist.
REFERENCES:
patent: 4369138 (1983-01-01), Lindall
patent: 4423037 (1983-12-01), Rosenblatt et al.
patent: 4508828 (1985-04-01), Lindall et al.
patent: 4656250 (1987-04-01), Morita et al.
patent: 6030790 (2000-02-01), Adermann et al.
patent: 6524788 (2003-02-01), Cantor
patent: 6689566 (2004-02-01), Cantor et al.
patent: 6743590 (2004-06-01), Cantor et al.
patent: 6923968 (2005-08-01), Cantor
patent: 33 47 548 (1985-07-01), None
patent: 44 34 551 (1996-04-01), None
patent: 0 783 522 (2001-12-01), None
patent: WO 91/06564 (1991-05-01), None
patent: WO 93/06845 (1993-04-01), None
patent: WO 94/03201 (1994-02-01), None
patent: WO 96/10041 (1996-04-01), None
Monier-Faugere et al., 2001, Kidney International, vol. 60, pp. 1460-1468.
Adermann et al., In:Innovations and Perspectives in Solid Phase Synthesis, Epton (ed.), Mayflower World Wide, Birmingham (1994) pp. 429-432.
Atkinson et al., Journal of Immunoassay (1982) 3(1):31-51.
Blind et al., Clin. Chem. (1987) 33(8): 1376-1381.
Bowie et al., Science (1990) 247:1306-1310.
Brossard et al., Journal of Clinical Endocrinology and Metabolism (1996) 81(11):3923-3929.
Campbell, Monoclonal Antibody and Immunosensor Technology, in Laboratory Techniques in Biochemistry and Molecular Biology, van der Vliet (ed.), Elsevier (1991) pp. 1-11, 42-45.
Caporale and Rosenblatt, Paraththyroid Hormone Antagonists Effective in vivo, in: Advances in Experimental Medicine and Biology, New York (1986) pp. 315-327.
Clinical Chemistry (1999) 45(6)Suppl:A97 b, Abstract Nos. 339-341.
D'Amour et al., Am. J. Physiol. (1986) 251:E680-E687.
Daniel et al., Virology (1994) 202:540-549.
Divieti, P. et al.,J Bone Miner Res(2001):Suppl I, S307.
Faugere, M.C. et al., (2001).Kidney International60:1460-1468.
Fischer et al., The Journal of Clinical Investigation (1974) 54:1382-1394.
Gao et al., Clinica Chimica Acta (1996) 245:39-59.
Goodman, W. et al., (2000).NEJM342:20, 1478-1483.
Gordon et al., Parathyroid Hormone Domain for Protein Kinase C Stimulation Located within Amphiphilic Helix, in: Peptides: Chemistry and Biology, Proceedings of the Twelfth American Peptide Symposium, Jun. 16-21, 1991, Cambridge, MA, Smith and River (eds.) Escom Science Publishers (1992) pp. 37-39.
Hashimoto et al., Journal of Cardiovascular Pharmacology (1981) 3(4):668-676.
Hehrmann et al., Journal of Immunoassay (1980) 1(2): 151-174.
John et al., Journal of Clinical Endocrinology and Metabolism (1999) 84(11):4287-4290.
LePage et al., Clin. Chem. (1998) 44:805-810.
Logue et al., Journal of Immunological Methods (1991) 137:159-166.
Mägerlein et al., Arzneim.-Forsch./Drug Res. (1998) 48(1):197-204.
Mägerlein et al., Arzneim.-Forsch./Drug Res. (1998) 48(11):783-787.
Mallette, Journal of Clinical Endocrinology and Metabolism (1980) 50(1);201-203.
Nakamura et al., Endocrinol. JPN (1981) 28(4):547-549.
Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., (eds.), Birkhäuser Boston (1994) pp. 492-495.
Niall et al., Proc. Natl. Acad. Sci. USA (1974) 71(2):384-388.
Nussbaum et al., Chemical Abstracts (1982) 96(5):181-192.
Nussbaum, SR et al., Clin. Chem. (1987) 33:1364-67.
Pang et al., Pharmacol. Exp. Ther. (1981) 216(3):567-571.
Qi et al., Am. J. Kidney Dis. (1995) 26:622-631.
Quarles et al., J. Clin. Endocrinol. Metab. (1992) 75:145-150.
Stadler,Homologous Radioimmunoassay for Human Parathyroid Hormone(Residues 1-34)with Biotinylated Peptide as Tracer, in Calcium Regulating Hormones, Vitamin D Metabolites, and Cyclic AMP Assays and their Clinical Application, Schmidt-Gayk et al., (eds.), Berlin/Heidelberg, Springer, (1990) pp. 137-150.
Tampe et al., J. Immunoassay (1992) 13(1): 1-13.
Visser et al., Acta Endocrinology (1979) 90:90-102.
Wingender et al., Structure-Function Relationship in Parathyroid Hormone in: Advances in Protein Design, International Workshop, Blöcker et al., (eds.), VCH (1988) pp. 167-176.
Zanelli et at., Journal of Immunoassay (1983) 4(2):175-206.
Zemplar package insert, Abbott Reference (1998) 06-9998-R1-Rev. Roche Laboratories.
U.S. Appl. No. 09/323,606, filed by Tom Cantor on Jan. 1, 1999.
U.S. Appl. No. 09/636,530, filed by Tom Cantor on Aug. 10, 2000.
U.S. Appl. No. 09/636,531, filed by Tom Cantor on Aug. 10, 2000.
U.S. Appl No. 09/928,048, filed by Tom Cantor on Aug. 10, 2001.
U.S. Appl. No. 60/224,396, filed by Tom Cantor on Aug. 10, 2000.
U.S. Appl. No. 10/265,276, filed by Tom Cantor on Oct. 3, 2002.
Faugere et al., Nephrology. Bone & Mineral Metabolism A3995.
Chernyshev Olga N.
Morrison & Foerster / LLP
Scantibodies Laboratory, Inc.
LandOfFree
Methods for monitoring and guiding therapeutic suppression... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for monitoring and guiding therapeutic suppression..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for monitoring and guiding therapeutic suppression... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3654766